7 results match your criteria: "Federal Armed Hospital Ulm[Affiliation]"
Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.
Eur J Haematol
April 2024
Department of Hematology and Oncology, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Article Synopsis
- Treatment intensification, particularly high-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT), significantly enhances outcomes for patients with primary central nervous system lymphoma (PCNSL).
- A multicenter analysis included 174 newly diagnosed PCNSL patients, assessing various prognostic risk scores (MSKCC, IELSG, and 3F) for their ability to predict overall survival (OS) and progression-free survival (PFS).
- Results showed that the 3F score was the most effective at stratifying risk groups and predicting outcomes, outperforming the other scores in both OS and PFS, demonstrating its clinical value in managing PCNSL patients with intensified treatment.
Prognostic impact of nutritional and inflammation-based risk scores in follicular lymphoma in the era of anti-CD20 targeted treatment strategies.
J Cancer Res Clin Oncol
July 2022
Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Background: The composition of the tumor microenvironment (TME) is conditioned by immunity and the inflammatory response. Nutritional and inflammation-based risk scores have emerged as relevant predictors of survival outcome across a variety of hematological malignancies.
Methods: In this retrospective multicenter trial, we ascertained the prognostic impact of established nutritional and inflammation-based risk scores [Glasgow Prognostic Score (GPS), C-reactive-protein/albumin ratio (CAR), neutrophil-lymphocyte ratio (NLR), prognostic nutritional index (PNI), and prognostic index (PI)] in 209 eligible patients with histologically confirmed CD20 follicular lymphoma (FL) of WHO grade 1 (37.
Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.
Blood Cancer J
May 2021
Hämatopathologie Lübeck, Reference Centre for Lymph Node Pathology and Haematopathology, Lübeck, Germany.
Epstein-Barr virus (EBV)-associated diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) constitute a distinct clinicopathological entity in the current World Health Organization (WHO) classification. However, its genomic features remain sparsely characterized. Here, we combine whole-genome sequencing (WGS), targeted amplicon sequencing (tNGS), and fluorescence in situ hybridization (FISH) from 47 EBV + DLBCL (NOS) cases to delineate the genomic landscape of this rare disease.
View Article and Find Full Text PDFExhaustion of tumour-infiltrating T-cell receptor repertoire diversity is an age-dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma.
Br J Haematol
April 2021
Department of Haematology and Oncology, University Hospital of Schleswig-Holstein, Luebeck, Germany.
Burkitt lymphoma (BL) is an aggressive B-cell-malignancy derived from germinal-centre B-cells. Curative therapy traditionally requires intensive immunochemotherapy. Recently, immuno-oncological approaches, modulating the T-cell tumour response, were approved for the treatment of a variety of malignancies.
View Article and Find Full Text PDFClinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients.
Blood Cancer J
May 2020
Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
Br J Haematol
April 2020
Department of Haematology and Oncology, University Hospital of Schleswig-Holstein, Lübeck, Germany.
Patients with EBV-positive diffuse large B cell lymphoma not otherwise specified (EBV DLBCL (NOS)) recurrently present with advanced age and reduced performance status. They are therefore insufficiently represented in clinical trials and treatment is likely to differ. Here we assess clinicopathological characteristics, therapeutic variability and clinical outcome in the largest consecutively diagnosed EBV DLBCL (NOS) cohort published to date (n = 80; median age 70 years; range 19-90).
View Article and Find Full Text PDFHuman leukocyte antigens and prognosis in patients with head and neck cancer: results of a prospective follow-up study.
Laryngoscope
April 2002
Department of ENT, Head and Neck Surgery, Federal Armed Hospital Ulm, Germany.
Background: Prognostic information is essential for optimal treatment of patients with head and neck cancer. We studied the relationship of class I and class II human leukocyte antigens (HLA) on prognosis in patients with head and neck cancer.
Methods: HLA-A, -B, -C and -DR antigens were determined in 209 patients with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.